Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Molecular Partners Ag (MOLN) Equity Ratio (2021 - 2025)

Historic Equity Ratio for Molecular Partners Ag (MOLN) over the last 5 years, with Q3 2025 value amounting to 0.85.

  • Molecular Partners Ag's Equity Ratio fell 534.78% to 0.85 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.85, marking a year-over-year decrease of 534.78%. This contributed to the annual value of 0.89 for FY2024, which is 44.64% up from last year.
  • Molecular Partners Ag's Equity Ratio amounted to 0.85 in Q3 2025, which was down 534.78% from 0.86 recorded in Q2 2025.
  • Molecular Partners Ag's Equity Ratio's 5-year high stood at 911802.46 during Q2 2024, with a 5-year trough of 0.62 in Q4 2021.
  • Moreover, its 5-year median value for Equity Ratio was 0.9 (2022), whereas its average is 168361.7.
  • Per our database at Business Quant, Molecular Partners Ag's Equity Ratio soared by 4431.2% in 2022 and then plummeted by 9999.99% in 2025.
  • Quarter analysis of 5 years shows Molecular Partners Ag's Equity Ratio stood at 0.62 in 2021, then soared by 44.31% to 0.9 in 2022, then decreased by 0.81% to 0.89 in 2023, then grew by 0.45% to 0.89 in 2024, then dropped by 4.66% to 0.85 in 2025.
  • Its Equity Ratio stands at 0.85 for Q3 2025, versus 0.86 for Q2 2025 and 0.91 for Q1 2025.